The association between HDL cholesterol and cardiovascular events, and the potential antiatherogenic effects of HDL particles, are altered in patients with established coronary heart disease. HDL particle composition has, therefore, gained attention after trials of therapies to increase HDL-cholesterol levels did not reduce the risk of an adverse cardiovascular event.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Martin, S. S. et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehu264.
Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).
HPS2-THRIVE Collaborative Group et al. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371, 203–212 (2014).
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B. & Dawber. T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62, 707–714 (1977).
Emerging Risk Factors Collaboration et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009).
Westerterp, M. et al. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ. Res. 114, 157–170 (2014).
Besler, C. et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 121, 2693–2708 (2011).
Riwanto, M. et al. Altered activation of endothelial anti-and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127, 891–904 (2013).
Davidson, W. S. et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29, 870–876 (2009).
Acknowledgements
U.L. is supported by a grant from the Fondation Leducq, the Swiss National Science Foundation (grant no 310030-149990) and from European-FP7 “Risky CAD”.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
U.L. has received research support, honoraria, or consultant fees from Amgen, Astra Zeneca, Merck Sharp & Dohme, Pfizer, Roche, and Sanofi-Aventis.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Landmesser, U. HDL and coronary heart disease—novel insights. Nat Rev Cardiol 11, 559–560 (2014). https://doi.org/10.1038/nrcardio.2014.128
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.128